A national priority

Health is the third pillar of the Presidential “Big Four Action Plan”. The Vision 2030 acknowledges the role of the private sector in enhancing the standard and coverage of healthcare services. With the development of a middle-class in Kenya INSERT AN INTERNAL LINK to INFOGRAPHIC 5 (and the related short description), the local pharmaceutical and wellbeing market is booming.

Investors in the health sector enjoy non-fiscal and fiscal incentives.

Kenya’s strong growth prospects are supported by an emerging middle class and an increasing appetite for high-value good and services.

Household final consumption per capita (in USD)
Source : Kenya National Bureau of Statistics

Preferential access to foreign markets

Goods originating from Kenya benefit from preferential access to main international markets (U.S.A, European Union, etc) and regional markets – East African Community (EAC) and Common Market for East and Southern Africa (COMESA). Kenya is already the largest producer of pharmaceutical goods in the COMESA region.

Target sectors

There are a number of opportunities in the health industry, including in the following sectors:

While there are 42 local registered pharmaceutical manufacturers (and one multinational – GlaxoSmithKline), most local companies do not meet the World Health Organization’s Good Manufacturing Practices, excluding them from international donor-funded procurements. Those procurements are worth an estimated of US$ 97 million per year. Kenya has a regional comparative advantage in the provision of medical services. Each year, 3,000 foreigners visit the country for “health reasons”. Furthermore, each year, about 10,000 Kenyans spend USD 100 million on specialized treatment overseas. Investors can get high returns in investing in large scale hospitals located in high density areas